Paul Allen - Celadon Pharmaceuticals CoFounder
| CEL Stock | 14.00 0.50 3.70% |
Founder
Paul Allen is CoFounder of Celadon Pharmaceuticals PLC
| Address | 71-75 Shelton Street, London, United Kingdom, WC2H 9JQ |
| Phone | 44 20 3150 0252 |
| Web | https://celadonpharma.com/ |
Paul Allen Latest Insider Activity
Tracking and analyzing the buying and selling activities of Paul Allen against Celadon Pharmaceuticals stock is an integral part of due diligence when investing in Celadon Pharmaceuticals. Paul Allen insider activity provides valuable insight into whether Celadon Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Celadon Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Celadon Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Paul Allen over two weeks ago Acquisition by Paul Allen of 300000 shares of Airship AI at 3.27 subject to Rule 16b-3 | ||
Paul Allen over two weeks ago Acquisition by Paul Allen of 100000 shares of Airship AI at 3.27 subject to Rule 16b-3 | ||
Paul Allen over six months ago Disposition of 30000 shares by Paul Allen of Airship AI at 3.3955 subject to Rule 16b-3 |
Celadon Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.344) % which means that it has lost $0.344 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.9071) %, meaning that it generated substantial loss on money invested by shareholders. Celadon Pharmaceuticals' management efficiency ratios could be used to measure how well Celadon Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At present, Celadon Pharmaceuticals' Total Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Intangible Assets is expected to grow to about 278.4 K, whereas Non Current Assets Total are forecasted to decline to about 5.3 M.Similar Executives
| Found 1 records | FOUNDER Age | ||
| Andrew Page | Alfa Financial Software | 62 | |
Management Performance
| Return On Equity | -1.91 | ||||
| Return On Asset | -0.34 |
Celadon Pharmaceuticals Leadership Team
Elected by the shareholders, the Celadon Pharmaceuticals' board of directors comprises two types of representatives: Celadon Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Celadon. The board's role is to monitor Celadon Pharmaceuticals' management team and ensure that shareholders' interests are well served. Celadon Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Celadon Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| James Short, CEO CoFounder | ||
| Kerin Williams, Company Secretary | ||
| Iqbal Gill, Chief Officer | ||
| CA BCOMM, CFO Director | ||
| Jonathan Turner, CFO Director | ||
| Paul Allen, CoFounder |
Celadon Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Celadon Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.91 | ||||
| Return On Asset | -0.34 | ||||
| Operating Margin | (36.89) % | ||||
| Current Valuation | 14.4 M | ||||
| Shares Outstanding | 68.85 M | ||||
| Shares Owned By Insiders | 64.80 % | ||||
| Shares Owned By Institutions | 11.23 % | ||||
| Price To Book | 3.97 X | ||||
| Price To Sales | 74.14 X | ||||
| Revenue | 75 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Celadon Stock
Celadon Pharmaceuticals financial ratios help investors to determine whether Celadon Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Celadon with respect to the benefits of owning Celadon Pharmaceuticals security.